Healthcare Equipment and Supplies
Company Overview of OptiScan Biomedical Corporation
OptiScan Biomedical Corporation develops glucose monitoring systems for the intensive care unit (ICU)/CCU. It offers OptiScanner, an automated, bedside glucose monitoring system to assist healthcare providers manage the glucose level of critically ill patients. The company’s OptiScanner provides serial blood glucose measurements for a range of glucose concentrations. OptiScan Biomedical Corporation was founded in 1994 and is based in Hayward, California.
24590 Clawiter Road
Hayward, CA 94545
Founded in 1994
Key Executives for OptiScan Biomedical Corporation
Chairman of the Board, Chief Executive Officer and President
Vice President of Finance & Administration and Controller
Vice President of Research and Development
Compensation as of Fiscal Year 2014.
OptiScan Biomedical Corporation Key Developments
Optiscan Biomedical Corporation Introduces its Next-Generation OptiScanner(TM) Product
Mar 21 14
OptiScan Biomedical Corporation introduced its next-generation OptiScanner(TM) product as part of a special symposium at the 34(th) International Symposium on Intensive Care and Emergency Medicine (ISICEM) being held this week in Brussels, Belgium. The new OptiScanner 6000 will build upon the company's current OptiScanner platform, a first-of-its-kind automated, bedside glucose monitoring system for the ICU, by incorporating the additional ability to monitor key hemodynamic analytes from the same single blood sample. The product will offer real-time monitoring of blood glucose combined with two leading components of cardiac output and oxygenation (hemoglobin and ScvO(2)). These expanded monitoring capabilities are designed to support clinical treatment decisions by providing Critical Care physicians with meaningful information to assess their patients' metabolic and hemodynamic status. The ISICEM symposium, entitled "New Insights into the Metabolic and Hemodynamic Status of the Critically Ill," featured several physician thought-leaders in the area of critical care. The speakers discussed the latest clinical data supporting the role of the current OptiScanner product (OptiScanner 5000) as a continuous glucose monitoring platform for critically ill patients, while also introducing the new OptiScanner 6000 as a first-of-its-kind approach to meeting the real-time, multi-analyte metabolic and hemodynamic monitoring needs of critical care physicians.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries